{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-23-000051","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.653413+00:00","generated_at":"2026-06-11T14:40:28.165190+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"vTv Therapeutics Q2 2023 net loss $5.6M ($0.07/shr); R&D spend up on cadisegliatin; Nasdaq extension granted","bullets":["Net loss of $5.6M ($0.07 per share) vs $3.2M ($0.04) in Q2 2022; no quarterly revenue.","R&D expenses $4.7M, up 113% from $2.2M, driven by cadisegliatin drug product costs.","Cash $12.6M at June 30, 2023, up modestly from $12.1M at Dec 31, 2022.","Nasdaq extended deadline to regain $1 bid compliance to Dec 18, 2023 (granted July 17).","Phase 3 study for cadisegliatin (TTP399) expected to initiate by year-end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-23-000051","json":"https://secwatch.observer/filing/0001641489-23-000051.json","markdown":"https://secwatch.observer/filing/0001641489-23-000051.md","text":"https://secwatch.observer/filing/0001641489-23-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000051/0001641489-23-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000051/vtvt-20230811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T14:40:28.165190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"440e992475f5279d81e61640adf6f270535b2d5a","claim":"vTv Therapeutics Inc. reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"On August 11, 2023, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000051/0001641489-23-000051-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}